Company Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe.
The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18.
The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets.
It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid.
Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
| Country | Israel |
| Founded | 1993 |
| IPO Date | Aug 11, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Anat Cohen-Dayag |
Contact Details
Address: Azrieli Center, Building D Holon, 5885849 Israel | |
| Phone | 972 3 765 8585 |
| Website | cgen.com |
Stock Details
| Ticker Symbol | CGEN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001119774 |
| CUSIP Number | M25722105 |
| ISIN Number | IL0010852080 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anat Cohen-Dayag Ph.D. | Chief Executive Officer, President and Director |
| Dr. Eran Ophir Ph.D. | Chief Scientific Officer |
| Dr. Zurit Levine Ph.D. | Senior Vice President of Technology Innovation |
| Dr. Pierre Ferre Ph.D. | Vice President of Preclinical Development |
| David Silberman CPA | Chief Financial Officer |
| Yvonne Naughton | Head of Investor Relations and Corporate Communications |
| Eran Ben Dor | General Counsel and Corporate Secretary |
| Dorit Amitay | Vice President of Human Resources |
| Dr. Yaron Turpaz M.B.A., Ph.D. | Senior Vice President and Senior Advisor of Data and Informatics Solutions |
| Rivka Schwartz | Vice President Research and Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 13, 2024 | 6-K | Report of foreign issuer |
| Aug 6, 2024 | 6-K | Report of foreign issuer |
| Aug 5, 2024 | 6-K | Report of foreign issuer |
| Jul 29, 2024 | 6-K | Report of foreign issuer |
| May 30, 2024 | 6-K | Report of foreign issuer |
| May 20, 2024 | 6-K | Report of foreign issuer |
| May 15, 2024 | 6-K | Report of foreign issuer |
| Mar 5, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 5, 2024 | 6-K | Report of foreign issuer |
| Feb 15, 2024 | 6-K | Report of foreign issuer |